|
US7244827B2
(en)
*
|
2000-04-12 |
2007-07-17 |
Agensys, Inc. |
Nucleic acid and corresponding protein entitled 24P4C12 useful in treatment and detection of cancer
|
|
US6943235B1
(en)
*
|
1999-04-12 |
2005-09-13 |
Agensys, Inc. |
Transmembrane protein expressed in prostate cancer
|
|
US20050255106A1
(en)
*
|
1999-05-22 |
2005-11-17 |
Linda Diehl |
Induction of anti-tumor ctl immunity through in vivo triggering of 4-1bb and/or cd40
|
|
US20030059427A1
(en)
*
|
2000-04-28 |
2003-03-27 |
Force Walker R. |
Isolation and characterization of highly active anti-CD40 antibody
|
|
CA2422204A1
(en)
|
2000-09-07 |
2002-03-14 |
John R. Schreiber |
Human antibodies against pseudomonas aeruginosa lps derived from transgenic mice
|
|
AU2004297218B2
(en)
|
2000-09-07 |
2012-03-01 |
Amgen, Inc. |
Human anti-Pseudomonas-aeruginosa antibodies derived from transgenic Xenomouse
|
|
EP2011802A3
(en)
|
2001-04-27 |
2009-04-15 |
Kyowa Hakko Kirin Co., Ltd. |
Anti-CD40 monoclonal antibody
|
|
US7658924B2
(en)
|
2001-10-11 |
2010-02-09 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
|
AR039067A1
(es)
*
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
|
US20040185040A1
(en)
|
2001-11-21 |
2004-09-23 |
Celltech R & D Limited |
Modulating immune responses
|
|
CA2466845A1
(en)
*
|
2001-11-21 |
2003-06-05 |
Fred Ramsdell |
Manipulation of cytokine levels using cd83 gene products
|
|
DK1531850T3
(da)
*
|
2002-06-07 |
2012-06-04 |
Zymogenetics Inc |
Anvendelse af 1L-21 og monoklonalt antistof til behandling af solide cancere
|
|
US7052694B2
(en)
*
|
2002-07-16 |
2006-05-30 |
Mayo Foundation For Medical Education And Research |
Dendritic cell potentiation
|
|
HN2004000285A
(es)
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTICUERPOS DIRIGIDOS A c-MET
|
|
EP2060270A3
(en)
*
|
2003-10-16 |
2009-12-09 |
Imclone LLC |
Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
|
|
JP4746552B2
(ja)
*
|
2003-11-04 |
2011-08-10 |
ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド |
自己免疫疾患および炎症性疾患ならびに臓器移植拒絶の処置のためのアンタゴニスト抗ｃｄ４０抗体の使用
|
|
US8277810B2
(en)
|
2003-11-04 |
2012-10-02 |
Novartis Vaccines & Diagnostics, Inc. |
Antagonist anti-CD40 antibodies
|
|
US20050136055A1
(en)
*
|
2003-12-22 |
2005-06-23 |
Pfizer Inc |
CD40 antibody formulation and methods
|
|
KR101223373B1
(ko)
|
2003-12-25 |
2013-01-16 |
교와 핫꼬 기린 가부시키가이샤 |
항 ｃｄ４０ 항체의 변이체
|
|
MX370489B
(es)
|
2004-01-09 |
2019-12-16 |
Pfizer |
Anticuerpos contra madcam.
|
|
BRPI0509201A
(pt)
|
2004-03-23 |
2007-08-28 |
Biogen Idec Inc |
agentes de acoplamento de receptor e usos terapêuticos destes
|
|
US20060099203A1
(en)
|
2004-11-05 |
2006-05-11 |
Pease Larry R |
B7-DC binding antibody
|
|
CA2572098C
(en)
*
|
2004-06-30 |
2015-01-27 |
Mayo Foundation For Medical Education And Research |
B7-dc binding antibody
|
|
JP5112863B2
(ja)
|
2004-07-01 |
2013-01-09 |
ノヴォ ノルディスク アー／エス |
ヒト抗−ｋｉｒ抗体
|
|
WO2006003179A2
(en)
|
2004-07-01 |
2006-01-12 |
Novo Nordisk A/S |
Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
|
|
US20070286855A1
(en)
*
|
2004-08-03 |
2007-12-13 |
Mayo Foundation For Medical Education And Research |
Improving treatments
|
|
US7563443B2
(en)
*
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
|
ES2374603T3
(es)
|
2005-01-06 |
2012-02-20 |
Novo Nordisk A/S |
Agentes de unión a kir y procedimientos de uso de los mismos.
|
|
US8716451B2
(en)
|
2005-01-12 |
2014-05-06 |
Kyowa Hakko Kirin Co., Ltd |
Stabilized human IgG2 and IgG3 antibodies
|
|
EP3312196B1
(en)
*
|
2005-03-23 |
2019-07-17 |
Genmab A/S |
Antibodies against cd38 for treatment of multiple myeloma
|
|
NZ562234A
(en)
|
2005-04-26 |
2009-09-25 |
Pfizer |
P-cadherin antibodies
|
|
PL1889065T3
(pl)
|
2005-05-18 |
2013-12-31 |
Novartis Ag |
Metody diagnostyki i leczenia chorób posiadających składnik autoimmunologiczny i/lub zapalny
|
|
JP5208730B2
(ja)
*
|
2005-05-18 |
2013-06-12 |
ノバルティス アーゲー |
Ｃｄ４０シグナル伝達によって媒介される増殖性障害の診断および治療のための方法
|
|
GB0512225D0
(en)
*
|
2005-06-16 |
2005-07-27 |
Univ Sheffield |
Immunoglobulin molecules
|
|
SI1912671T1
(en)
|
2005-07-18 |
2018-01-31 |
Seattle Genetics, Inc. |
Conjugates beta-glucuronide linker-drug
|
|
KR101536506B1
(ko)
|
2005-09-07 |
2015-07-14 |
암젠 프레몬트 인코포레이티드 |
액티빈 수용체 유사 키나제-1에 대한 인간 모노클로날 항체
|
|
WO2007103048A2
(en)
*
|
2006-03-01 |
2007-09-13 |
Regents Of The University Of Colorado |
Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
|
|
EP2589654A1
(en)
|
2006-05-03 |
2013-05-08 |
The Regents of the University of Colorado, a body corporate |
CD40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
|
|
EP1854810A1
(en)
*
|
2006-05-09 |
2007-11-14 |
PanGenetics B.V. |
Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
|
|
MX2008013990A
(es)
|
2006-05-09 |
2009-01-29 |
Pfizer Prod Inc |
Derivados de cicloalquilamino acidos.
|
|
CA2652148C
(en)
*
|
2006-05-12 |
2016-10-04 |
Fondazione Centro San Raffaele Del Monte Tabor |
Tolerogenic dendritic cells, method for their production and uses thereof
|
|
US20090074711A1
(en)
*
|
2006-09-07 |
2009-03-19 |
University Of Southhampton |
Human therapies using chimeric agonistic anti-human cd40 antibody
|
|
CA2672581A1
(en)
*
|
2006-12-14 |
2008-06-19 |
Forerunner Pharma Research Co., Ltd. |
Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
|
|
SG178804A1
(en)
*
|
2007-02-23 |
2012-03-29 |
Schering Corp |
Engineered anti-il-23p19 antibodies
|
|
DK2426144T3
(en)
*
|
2007-02-23 |
2019-01-07 |
Merck Sharp & Dohme |
Manipulated Anti-IL-23P19 Antibodies
|
|
AU2008260498B2
(en)
|
2007-05-30 |
2012-11-29 |
Xencor, Inc. |
Methods and compositions for inhibiting CD32b expressing cells
|
|
EP1997830A1
(en)
*
|
2007-06-01 |
2008-12-03 |
AIMM Therapeutics B.V. |
RSV specific binding molecules and means for producing them
|
|
US8039597B2
(en)
*
|
2007-09-07 |
2011-10-18 |
Agensys, Inc. |
Antibodies and related molecules that bind to 24P4C12 proteins
|
|
BRPI0820707A2
(pt)
|
2007-11-07 |
2015-06-16 |
Genentech Inc |
Métodos e composição para avaliar a responsividade do linfoma de células b para o tratamento com anticorpos anti-cd40
|
|
KR101577843B1
(ko)
|
2007-12-14 |
2015-12-16 |
브리스톨-마이어스 스큅 컴퍼니 |
인간 ｏｘ４０ 수용체에 대한 결합 분자
|
|
JO2913B1
(en)
*
|
2008-02-20 |
2015-09-15 |
امجين إنك, |
Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
|
|
US8518410B2
(en)
*
|
2009-03-10 |
2013-08-27 |
Baylor Research Institute |
Fusion protein with HIV antigen
|
|
JP5576370B2
(ja)
|
2008-08-06 |
2014-08-20 |
ファイザー・インク |
Ｃｈｋ−１阻害剤としての６置換２−ヘテロシクリルアミノピラジン化合物
|
|
CN102170908A
(zh)
*
|
2008-08-29 |
2011-08-31 |
莱顿大学医学中心附属莱顿教学医院 |
向个体的肿瘤引流淋巴结递送cd40激动剂
|
|
EP2198878A1
(en)
|
2008-12-18 |
2010-06-23 |
University Of Miami |
Polypeptide bombesin antagonists
|
|
JO3382B1
(ar)
*
|
2008-12-23 |
2019-03-13 |
Amgen Inc |
أجسام مضادة ترتبط مع مستقبل cgrp بشري
|
|
AU2016244220B2
(en)
*
|
2008-12-23 |
2018-05-17 |
Amgen Inc. |
Human CGRP receptor binding proteins
|
|
CA2754531A1
(en)
*
|
2009-03-06 |
2010-09-30 |
Seattle Genetics, Inc. |
Antibody drug conjugates (adc) that bind to 24p4c12 proteins
|
|
EP2406288B1
(en)
|
2009-03-10 |
2016-12-14 |
Baylor Research Institute |
Antigen presenting cell targeted vaccines
|
|
AU2010222942B2
(en)
*
|
2009-03-10 |
2013-01-10 |
Baylor Research Institute |
Anti-CD40 antibodies and uses thereof
|
|
CA2758523C
(en)
|
2009-04-18 |
2019-03-12 |
Genentech, Inc. |
Methods for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies
|
|
EP2993188B1
(en)
*
|
2009-04-20 |
2020-08-19 |
Kyowa Kirin Co., Ltd. |
Anti cd40 antibody containing igg2 having three amino acid mutations introduced therein
|
|
TW201138843A
(en)
|
2009-12-18 |
2011-11-16 |
Colgate Palmolive Co |
Biguanide preservation of precipitated calcium carbonate
|
|
WO2011083391A2
(en)
|
2010-01-05 |
2011-07-14 |
Pfizer Inc. |
Biomarkers for anti-igf-ir cancer therapy
|
|
NZ602020A
(en)
|
2010-03-31 |
2014-05-30 |
Boehringer Ingelheim Int |
Anti-cd40 antibodies
|
|
GB201006096D0
(en)
*
|
2010-04-13 |
2010-05-26 |
Alligator Bioscience Ab |
Novel compositions and uses thereof
|
|
FR2959994B1
(fr)
|
2010-05-12 |
2012-08-24 |
Lfb Biotechnologies |
Nouveaux anticorps humanises 12g4 mutes et leurs fragments diriges contre le recepteur humain de l'hormone anti-mullerienne de type ii
|
|
SG10201912092VA
(en)
|
2010-09-09 |
2020-02-27 |
Pfizer |
4-1bb binding molecules
|
|
EP2621951A1
(en)
*
|
2010-09-29 |
2013-08-07 |
Université de Liège |
Combination of an agonistic anti-cd40 monoclonal antibody or a cd40 ligand and inactivated or attenuated bacteria for use in the treatment and/or prevention of mastitis
|
|
AR083847A1
(es)
|
2010-11-15 |
2013-03-27 |
Novartis Ag |
Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
|
|
US20130273055A1
(en)
*
|
2010-11-16 |
2013-10-17 |
Eric Borges |
Agents and methods for treating diseases that correlate with bcma expression
|
|
DK2663580T3
(en)
*
|
2011-01-10 |
2017-03-13 |
Ct Atlantic Ltd |
COMBINATION THERAPY INCLUDING TUMOR ASSOCIATED ANTI-BINDING ANTIBODIES
|
|
GB201103578D0
(en)
|
2011-03-02 |
2011-04-13 |
Sabrepharm Ltd |
Dipyridinium derivatives
|
|
PT2683406T
(pt)
*
|
2011-03-11 |
2019-07-08 |
Beth Israel Deaconess Medical Ct Inc |
Anticorpos anti-cd40 e utilização dos mesmos
|
|
EP2699598B1
(en)
|
2011-04-19 |
2019-03-06 |
Pfizer Inc |
Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
|
|
WO2012145746A1
(en)
*
|
2011-04-21 |
2012-10-26 |
The Regents Of The University Of Colorado, A Body Corporate |
Compositions and methods for the treatment of neuromyelitis optica
|
|
US9475879B2
(en)
|
2011-04-21 |
2016-10-25 |
Bristol-Myers Squibb Company |
Antibody polypeptides that antagonize CD40
|
|
ES2709654T3
(es)
*
|
2011-04-29 |
2019-04-17 |
Apexigen Inc |
Anticuerpos anti-CD40 y métodos de uso
|
|
WO2012158818A2
(en)
|
2011-05-16 |
2012-11-22 |
Fabion Pharmaceuticals, Inc. |
Multi-specific fab fusion proteins and methods of use
|
|
GB201115280D0
(en)
|
2011-09-05 |
2011-10-19 |
Alligator Bioscience Ab |
Antibodies, uses and methods
|
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
|
ES2806146T3
(es)
|
2011-09-22 |
2021-02-16 |
Amgen Inc |
Proteínas de unión al antígeno CD27L
|
|
WO2013059885A2
(en)
|
2011-10-28 |
2013-05-02 |
Cephalon Australia Pty Ltd |
Polypeptide constructs and uses thereof
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
WO2013091661A2
(en)
*
|
2011-12-23 |
2013-06-27 |
Aarhus Universitet |
Proteolytic resistant protein affinity tag
|
|
AU2013215254B2
(en)
|
2012-01-31 |
2017-08-31 |
Regeneron Pharmaceuticals, Inc. |
Anti-ASIC1 antibodies and uses thereof
|
|
JP5798199B2
(ja)
*
|
2012-03-08 |
2015-10-21 |
国立研究開発法人科学技術振興機構 |
抗がん剤
|
|
AR090263A1
(es)
*
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
RU2737765C2
(ru)
|
2012-05-04 |
2020-12-02 |
Пфайзер Инк. |
Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин
|
|
US20140004131A1
(en)
|
2012-05-04 |
2014-01-02 |
Novartis Ag |
Antibody formulation
|
|
WO2013192215A1
(en)
|
2012-06-18 |
2013-12-27 |
Yale University |
Compositions and methods for diminishing an immune response
|
|
CN104918957B
(zh)
*
|
2012-10-30 |
2018-11-16 |
埃派斯进有限公司 |
抗-cd40抗体及其使用方法
|
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
|
PT2951208T
(pt)
|
2013-02-01 |
2019-12-30 |
Univ California |
Anticorpos anti-cd83 e sua utilização
|
|
WO2014144817A2
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Inc. |
Inhibitory polypeptides specific to wnt inhibitors
|
|
MD20180107A2
(ro)
|
2013-03-18 |
2019-06-30 |
Biocerox Products B.V. |
Anticorpi anti-CD134 (OX40) umanizaţi şi utilizarea acestora
|
|
CA2909952C
(en)
|
2013-04-29 |
2021-10-12 |
Teva Pharmaceuticals Australia Pty Ltd. |
Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
|
|
US11117975B2
(en)
|
2013-04-29 |
2021-09-14 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
|
|
CN112516179A
(zh)
|
2013-06-14 |
2021-03-19 |
普赛奥克苏斯治疗公司 |
用于b型腺病毒的给药方案及制剂
|
|
BR112015031164B1
(pt)
|
2013-06-17 |
2019-03-19 |
Koninklijke Philips N.V. |
Conjunto de suporte para um indivíduo para um sistema de imageamento por ressonância magnética, e, sistema de imageamento por ressonância magnética utilizando o suporte
|
|
GB201311487D0
(en)
*
|
2013-06-27 |
2013-08-14 |
Alligator Bioscience Ab |
Bispecific molecules
|
|
CA2919725C
(en)
|
2013-08-08 |
2023-04-18 |
Cytune Pharma |
An il-15 and il-15r.aplha. sushi domain based modulokines
|
|
CA2923145C
(en)
|
2013-09-05 |
2025-09-16 |
Amgen Inc. |
MOLECULES CONTAINING FCS AND EXHIBITING PREDICTABLE, UNIFORM AND REPRODUCIBLE GLYCOFORM PROFILES
|
|
AR097584A1
(es)
|
2013-09-12 |
2016-03-23 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
|
|
SG11201602887QA
(en)
|
2013-10-25 |
2016-05-30 |
Psioxus Therapeutics Ltd |
Oncolytic adenoviruses armed with heterologous genes
|
|
GB201322583D0
(en)
*
|
2013-12-19 |
2014-02-05 |
Alligator Bioscience Ab |
Antibodies
|
|
WO2015091655A1
(en)
*
|
2013-12-20 |
2015-06-25 |
F. Hoffmann-La Roche Ag |
Combination therapy with an anti-ang2 antibody and a cd40 agonist
|
|
EP3094652B1
(en)
|
2014-01-13 |
2021-09-29 |
Baylor Research Institute |
Novel vaccines against hpv and hpv-related diseases
|
|
WO2015134988A1
(en)
|
2014-03-07 |
2015-09-11 |
Bristol-Myers Squibb Company |
Method of using antibody polypeptides that antagonize cd40 to treat ibd
|
|
WO2015153514A1
(en)
|
2014-03-31 |
2015-10-08 |
Genentech, Inc. |
Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
|
|
KR102526945B1
(ko)
*
|
2014-04-30 |
2023-04-27 |
막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 |
Ｃｄ269에 대한 인간화 항체
|
|
UA119352C2
(uk)
|
2014-05-01 |
2019-06-10 |
Тева Фармасьютикалз Острейліа Пті Лтд |
Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
|
|
MX377275B
(es)
|
2014-05-16 |
2025-03-07 |
Amgen Inc |
Ensayo para detectar poblaciones celulares linfocitos t colaboradores 1 (th1) y linfocitos t colaboradores (th2).
|
|
GB201413665D0
(en)
|
2014-07-03 |
2014-09-17 |
Transimmune Ag And Yale University |
Method for obtaining globally activated monocytes
|
|
KR102443258B1
(ko)
|
2014-08-12 |
2022-09-14 |
엘리게이터 바이오사이언스 에이비 |
항 cd40 항체에 의한 병용 치료제
|
|
EP3070102A1
(en)
|
2015-03-18 |
2016-09-21 |
F. Hoffmann-La Roche AG |
Combination therapy of antibodies human cd40 activating antibodies and anti human pld-1 antibodies
|
|
RU2017108173A
(ru)
*
|
2014-08-14 |
2018-09-17 |
Ф.Хоффманн-Ля Рош Аг |
Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1
|
|
MX2017003247A
(es)
|
2014-09-15 |
2017-11-30 |
Amgen Inc |
Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas.
|
|
US10870704B2
(en)
|
2014-10-23 |
2020-12-22 |
Kira Biotech Pty Limited |
CD83 binding proteins and uses thereof
|
|
US9815886B2
(en)
|
2014-10-28 |
2017-11-14 |
Adma Biologics, Inc. |
Compositions and methods for the treatment of immunodeficiency
|
|
HUE054075T2
(hu)
*
|
2014-10-29 |
2021-08-30 |
Seagen Inc |
CD40 elleni nem fukozilált antitestek adagolása és bevitele
|
|
UA125637C2
(uk)
|
2014-10-29 |
2022-05-11 |
Тева Фармасьютікалз Острейліа Пті Лтд |
ЗЛИТИЙ ПОЛІПЕПТИД ІНТЕРФЕРОНУ <font face="Symbol">a2</font>b
|
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗ｐｄ－１抗體類和使用彼等之方法
|
|
BR112017020952A2
(pt)
|
2015-04-13 |
2018-07-10 |
Five Prime Therapeutics Inc |
método de tratamento de câncer, composição e uso da composição
|
|
TWI728953B
(zh)
|
2015-04-24 |
2021-06-01 |
美商安美基公司 |
治療或預防偏頭痛之方法
|
|
SG11201708604TA
(en)
|
2015-04-30 |
2017-11-29 |
Psioxus Therapeutics Ltd |
Oncolytic adenovirus encoding a b7 protein
|
|
CR20210429A
(es)
|
2015-06-24 |
2021-09-24 |
Hoffmann La Roche |
ANTICUERPOS ANTI-RECEPTOR DE TRANSFERRINA CON AFINIDAD DISEÑADA (Divisional 2017-0562)
|
|
US10479838B2
(en)
*
|
2015-06-29 |
2019-11-19 |
Bristol-Myers Squibb Company |
Antibodies to CD40 with enhanced agonist activity
|
|
KR102671348B1
(ko)
*
|
2015-06-29 |
2024-05-30 |
브리스톨-마이어스 스큅 컴퍼니 |
Cd40에 대한 항체
|
|
EP3744340A3
(en)
|
2015-07-16 |
2021-03-03 |
Biokine Therapeutics Ltd. |
Compositions and methods for treating cancer
|
|
HUE056769T2
(hu)
|
2015-09-04 |
2022-03-28 |
Primatope Therapeutics Inc |
Humanizált anti-CD40 antitestek és felhasználásuk
|
|
BR112018006360A2
(pt)
*
|
2015-09-30 |
2018-10-09 |
Janssen Biotech Inc |
anticorpos agonísticos que se ligam especificamente ao cd40 humano e métodos de uso
|
|
TWI819458B
(zh)
|
2015-10-02 |
2023-10-21 |
瑞士商赫孚孟拉羅股份公司 |
雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法
|
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
|
GB2543550A
(en)
|
2015-10-21 |
2017-04-26 |
Hox Therapeutics Ltd |
Peptides
|
|
KR20250099459A
(ko)
|
2015-11-03 |
2025-07-01 |
얀센 바이오테크 인코포레이티드 |
Pd-1과 특이적으로 결합하는 항체 및 그의 용도
|
|
CN114835795A
(zh)
*
|
2015-11-16 |
2022-08-02 |
Ubi蛋白公司 |
用于延长蛋白质半衰期的方法
|
|
EP3386536A4
(en)
*
|
2015-12-07 |
2019-07-31 |
Opi Vi- IP Holdco LLC |
COMPOSITION OF ANTIBODY CONSTRUCT AGONIST CONJUGATES AND METHOD FOR USE THEREOF
|
|
EA201891022A1
(ru)
|
2015-12-17 |
2019-01-31 |
Псайоксус Терапьютикс Лимитед |
Вирус, кодирующий антитело к комплексу tcr или фрагмент указанного антитела
|
|
KR20180114223A
(ko)
*
|
2016-03-04 |
2018-10-17 |
더 락커펠러 유니버시티 |
증진된 효능제 활성을 갖는 cd40에 대한 항체
|
|
ES3041500T3
(en)
|
2016-03-10 |
2025-11-12 |
Cg Oncology Inc |
Methods of treating solid tumors by combination therapy
|
|
JP7034489B2
(ja)
|
2016-03-15 |
2022-03-14 |
アイタブメッド （エイチケイ） リミテッド |
多重特異性Ｆａｂ融合タンパクおよびその使用
|
|
CN109069638B
(zh)
|
2016-03-24 |
2022-03-29 |
璟尚生物制药公司 |
用于癌症治疗的三特异性抑制剂
|
|
KR102626498B1
(ko)
|
2016-03-25 |
2024-01-19 |
씨젠 인크. |
페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정
|
|
UA123111C2
(uk)
|
2016-05-27 |
2021-02-17 |
Еббві Байотерапьютікс Інк. |
Антитіло до cd40 та його застосування
|
|
KR20190014525A
(ko)
|
2016-05-27 |
2019-02-12 |
애브비 바이오테라퓨틱스 인크. |
면역 조절 단백질과 종양 항원을 결합하는 이중특이적 결합 단백질
|
|
PL3468997T3
(pl)
|
2016-06-08 |
2024-12-16 |
Xencor, Inc. |
Leczenie chorób związanych z lgG4 przeciwciałami anty-CD19 wiążącymi się krzyżowo z CD32b
|
|
WO2017211321A1
(zh)
|
2016-06-08 |
2017-12-14 |
上海交通大学医学院 |
增强激动型抗体活性的抗体重链恒定区序列
|
|
JP7461741B2
(ja)
|
2016-06-20 |
2024-04-04 |
カイマブ・リミテッド |
抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
|
|
UA128304C2
(uk)
|
2016-07-14 |
2024-06-05 |
Ґенмаб А/С |
Мультиспецифічне антитіло до cd40 і cd137
|
|
US11618784B2
(en)
|
2016-07-19 |
2023-04-04 |
Teva Pharmaceuticals Australia Pty Ltd. |
Anti-CD47 combination therapy
|
|
MA45919A
(fr)
|
2016-08-12 |
2019-06-19 |
Janssen Biotech Inc |
Conception d'anticorps modifiés et d'autres molécules contenant un domaine fc présentant des fonctions d'agonisme et d'effecteur améliorées
|
|
JP7009448B2
(ja)
|
2016-08-12 |
2022-02-10 |
ヤンセン バイオテツク，インコーポレーテツド |
強化されたアゴニスト活性を有する、Ｆｃが遺伝子操作を受けた抗ＴＮＦＲスーパーファミリーメンバー抗体及びその使用方法
|
|
JP7138094B2
(ja)
|
2016-08-25 |
2022-09-15 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
マクロファージ活性化剤と組み合わせた抗ｃｓｆ－１ｒ抗体の間欠投与
|
|
GB201713765D0
(en)
|
2017-08-28 |
2017-10-11 |
Psioxus Therapeutics Ltd |
Modified adenovirus
|
|
MY197324A
(en)
|
2016-08-29 |
2023-06-13 |
Akamis Bio Ltd |
Adenovirus armed with bispecific t cell activator
|
|
WO2018088850A2
(ko)
|
2016-11-11 |
2018-05-17 |
다이노나(주) |
Cd40에 특이적으로 결합하는 항체 및 그의 용도
|
|
JP2020504105A
(ja)
|
2016-12-19 |
2020-02-06 |
グレンマーク・ファーマシューティカルズ・エスエー |
新規なｔｎｆｒアゴニストおよびその使用
|
|
JP7304287B2
(ja)
|
2016-12-22 |
2023-07-06 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗ｐｄ－ｌ１／ｐｄ１治療の不成功後の、抗ｐｄ－ｌ１抗体との組み合わせでの抗ｃｓｆ－１ｒ抗体を用いた腫瘍の治療
|
|
CN109071656B
(zh)
|
2017-01-05 |
2021-05-18 |
璟尚生物制药公司 |
检查点调节物拮抗剂
|
|
CA3049842A1
(en)
*
|
2017-02-02 |
2018-08-09 |
Silverback Therapeutics, Inc. |
Construct-peptide compositions and methods of use thereof
|
|
AU2018218345B2
(en)
|
2017-02-10 |
2025-04-03 |
Genmab B.V. |
Polypeptide variants and uses thereof
|
|
AU2018235928B2
(en)
|
2017-03-14 |
2023-09-21 |
Amgen Inc. |
Control of total afucosylated glycoforms of antibodies produced in cell culture
|
|
US10259865B2
(en)
|
2017-03-15 |
2019-04-16 |
Adma Biologics, Inc. |
Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
|
|
US11730822B2
(en)
|
2017-03-24 |
2023-08-22 |
Seagen Inc. |
Process for the preparation of glucuronide drug-linkers and intermediates thereof
|
|
EP3601348A1
(en)
*
|
2017-03-29 |
2020-02-05 |
Glycotope GmbH |
Humanized anti-cd40 antibodies
|
|
EP3604385B1
(en)
|
2017-03-30 |
2024-05-01 |
NOF Corporation |
Heterobifunctional monodispersed polyethylene glycol and conjugate using the same
|
|
US11319408B2
(en)
|
2017-03-30 |
2022-05-03 |
Nof Corporation |
Hydrophilic polymer derivative having self-immolative acetal linker and conjugate using same
|
|
TWI704158B
(zh)
|
2017-04-04 |
2020-09-11 |
瑞士商赫孚孟拉羅股份公司 |
能夠特異性結合至cd40及fap之新穎雙特異性抗原結合分子
|
|
CA3058279A1
(en)
|
2017-04-13 |
2018-10-18 |
F.Hoffmann-La Roche Ag |
An interleukin-2 immunoconjugate, a cd40 agonist, and optionally a pd-1 axis binding antagonist for use in methods of treating cancer
|
|
US11525005B2
(en)
|
2017-06-01 |
2022-12-13 |
Jiangsu Hengrui Medicine Co., Ltd. |
Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof
|
|
JP7394628B2
(ja)
*
|
2017-06-01 |
2023-12-08 |
アカミス バイオ リミテッド |
腫瘍溶解性ウイルスおよび方法
|
|
CN110506058A
(zh)
*
|
2017-06-02 |
2019-11-26 |
豪夫迈·罗氏有限公司 |
免疫激动剂的施用路径
|
|
EP3418302A1
(en)
|
2017-06-19 |
2018-12-26 |
F. Hoffmann-La Roche AG |
Administration routes for immune agonists
|
|
AU2018300189B2
(en)
|
2017-07-14 |
2025-05-15 |
Pfizer, Inc. |
Antibodies to MAdCAM
|
|
IL272159B2
(en)
|
2017-08-04 |
2026-03-01 |
Genmab As |
PD-L1 and CD137 binding agents and their use
|
|
CN111511762B
(zh)
|
2017-08-21 |
2025-05-06 |
天演药业公司 |
抗cd137分子及其用途
|
|
JP7346390B2
(ja)
*
|
2017-09-19 |
2023-09-19 |
マブ ディスカバリー ゲゼルシャフト ミット ベシュレンクテル ハフツング |
アゴニスト性ｃｄ４０抗体
|
|
US10610585B2
(en)
|
2017-09-26 |
2020-04-07 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating and preventing HIV
|
|
KR102782136B1
(ko)
|
2017-11-08 |
2025-03-18 |
쿄와 기린 가부시키가이샤 |
CD40과 EpCAM에 결합하는 이중특이적 항체
|
|
JP7284759B2
(ja)
|
2017-12-27 |
2023-05-31 |
ブリストル－マイヤーズ スクイブ カンパニー |
抗ｃｄ４０抗体およびその使用
|
|
CN109971717B
(zh)
*
|
2017-12-28 |
2023-06-20 |
上海细胞治疗研究院 |
共表达cd40抗体与间皮素特异性嵌合抗原受体的t细胞及其用途
|
|
CN109971723B
(zh)
*
|
2017-12-28 |
2023-07-07 |
上海细胞治疗研究院 |
包含CD40抗体与muc1特异性嵌合抗原受体基因的T细胞及其用途
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
GB201801614D0
(en)
|
2018-01-31 |
2018-03-14 |
Psioxus Therapeutics Ltd |
Formulation
|
|
WO2019148445A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Precision/context-dependent activatable antibodies, and methods of making and using the same
|
|
WO2019148444A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Anti-ctla4 antibodies and methods of making and using the same
|
|
US12091502B2
(en)
|
2018-03-13 |
2024-09-17 |
Nof Corporation |
Heterobifunctional compound having monodispersed polyethylene glycol in main chain and side chain
|
|
CN119639849A
(zh)
|
2018-03-26 |
2025-03-18 |
美国安进公司 |
细胞培养物中产生的抗体的总去岩藻糖基化糖型
|
|
EP3774881A1
(en)
|
2018-04-02 |
2021-02-17 |
Amgen Inc. |
Erenumab compositions and uses thereof
|
|
CN112512572B
(zh)
|
2018-04-20 |
2024-12-10 |
礼进生物医药科技（上海）有限公司 |
抗cd40抗体及其用途
|
|
TW202003576A
(zh)
*
|
2018-05-10 |
2020-01-16 |
美商艾博視訊有限公司 |
活化cd40之單株抗體及其用途
|
|
US20190365719A1
(en)
*
|
2018-06-01 |
2019-12-05 |
Massachusetts Institute Of Technology |
Combination treatments of hsp90 inhibitors for enhancing tumor immunogenicity and methods of use thereof
|
|
MA52889A
(fr)
|
2018-06-15 |
2021-04-21 |
Flagship Pioneering Innovations V Inc |
Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires
|
|
WO2020006516A1
(en)
|
2018-06-29 |
2020-01-02 |
Gensun Biopharma, Inc. |
Antitumor immune checkpoint regulator antagonists
|
|
CA3109905A1
(en)
|
2018-08-20 |
2020-02-27 |
Pfizer Inc. |
Anti-gdf15 antibodies, compositions and methods of use
|
|
US12460000B2
(en)
|
2018-09-07 |
2025-11-04 |
Itabmed (Hk) Limited |
Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof
|
|
US20210355216A1
(en)
|
2018-10-05 |
2021-11-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Methods and systems for controlling the agonistic properties of antibody variable domains by light
|
|
BR112021009835A2
(pt)
|
2018-11-30 |
2021-08-17 |
Jiangsu Hengrui Medicine Co., Ltd. |
anticorpo anti-cd40, fragmento de ligação ao antígeno e uso farmacêutico dos mesmos
|
|
MX2021006360A
(es)
|
2018-11-30 |
2021-08-11 |
Jiangsu Hengrui Medicine Co |
Composicion farmaceutica de anticuerpo cd40 y uso de la misma.
|
|
WO2020132810A1
(en)
|
2018-12-24 |
2020-07-02 |
Generon (Shanghai) Corporation Ltd. |
Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
|
|
WO2020154335A1
(en)
*
|
2019-01-22 |
2020-07-30 |
Revmab Biosciences Usa, Inc. |
Novel anti-cd40 antibodies
|
|
US10570210B1
(en)
|
2019-03-04 |
2020-02-25 |
Beijing Mabworks Biotech Co.Ltd |
Antibodies binding CD40 and uses thereof
|
|
EP3947454A1
(en)
|
2019-03-27 |
2022-02-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Recombinant proteins with cd40 activating properties
|
|
CN113728008B
(zh)
*
|
2019-04-10 |
2024-04-09 |
南开大学 |
抗cd40抗体及其用途
|
|
EP3962493A2
(en)
|
2019-05-03 |
2022-03-09 |
Flagship Pioneering Innovations V, Inc. |
Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
|
|
US12466891B2
(en)
|
2019-05-15 |
2025-11-11 |
Kyowa Kirin Co., Ltd. |
Bispecific antibody binding to CD40 and GPC3
|
|
JPWO2020230899A1
(enExample)
|
2019-05-15 |
2020-11-19 |
|
|
|
EP3990116A1
(en)
|
2019-06-28 |
2022-05-04 |
Gensun Biopharma Inc. |
ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFß1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
|
|
US20220370418A1
(en)
|
2019-09-09 |
2022-11-24 |
Basilea Pharmaceutica International AG |
Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
|
|
AU2020355251A1
(en)
|
2019-09-26 |
2022-04-21 |
Amgen Inc. |
Methods of producing antibody compositions
|
|
WO2021060439A1
(ja)
|
2019-09-26 |
2021-04-01 |
日油株式会社 |
ペプチドリンカーを有するヘテロ二官能性単分散ポリエチレングリコール
|
|
EP4069291A1
(en)
*
|
2019-12-03 |
2022-10-12 |
Evotec International GmbH |
Interferon-associated antigen binding proteins and uses thereof
|
|
US20230114107A1
(en)
|
2019-12-17 |
2023-04-13 |
Flagship Pioneering Innovations V, Inc. |
Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
|
|
JP2023507323A
(ja)
|
2019-12-20 |
2023-02-22 |
アムジエン・インコーポレーテツド |
固形腫瘍の治療のためのメソセリン標的化ｃｄ４０アゴニスト多重特異性抗体コンストラクト
|
|
US20210214454A1
(en)
*
|
2020-01-10 |
2021-07-15 |
Symphogen A/S |
Anti-cd40 antibodies and compositions
|
|
IL272194A
(en)
|
2020-01-22 |
2021-07-29 |
Yeda Res & Dev |
Multispecific antibodies for use in treating diseases
|
|
JP7796389B2
(ja)
|
2020-04-23 |
2026-01-09 |
ブライトパス・バイオ株式会社 |
改良ペプチドワクチン
|
|
WO2021228178A1
(en)
|
2020-05-13 |
2021-11-18 |
Adagene Ag |
Compositions and methods for treating cancer
|
|
EP4149959A1
(en)
|
2020-05-14 |
2023-03-22 |
Molecular Partners AG |
Multispecific proteins
|
|
WO2021229076A1
(en)
|
2020-05-14 |
2021-11-18 |
Molecular Partners Ag |
Recombinant cd40 binding proteins and their use
|
|
JP7858550B2
(ja)
|
2020-05-26 |
2026-05-14 |
アンスティチュート、ナシオナル、ドゥ、ラ、サンテ、エ、ドゥ、ラ、ルシェルシュ、メディカル |
重症急性呼吸器症候群コロナウイルス２（ｓａｒｓ－ｃｏｖ－２）ポリペプチドおよびワクチン目的でのその使用
|
|
GB202008003D0
(en)
|
2020-05-28 |
2020-07-15 |
Quine Medical Ab |
Anti-CD40 antibody
|
|
KR20230020521A
(ko)
*
|
2020-06-04 |
2023-02-10 |
셀벡스 피티와이 리미티드 |
아고니스트 항-cd40 항체
|
|
WO2021247892A1
(en)
|
2020-06-04 |
2021-12-09 |
Amgen Inc. |
Assessment of cleaning procedures of a biotherapeutic manufacturing process
|
|
EP4172323A1
(en)
|
2020-06-29 |
2023-05-03 |
Flagship Pioneering Innovations V, Inc. |
Viruses engineered to promote thanotransmission and their use in treating cancer
|
|
CN116234909A
(zh)
*
|
2020-08-21 |
2023-06-06 |
上海药明生物技术有限公司 |
Cd40激动剂抗体和使用方法
|
|
AU2021360897A1
(en)
|
2020-10-15 |
2023-05-25 |
Amgen Inc. |
Relative unpaired glycans in antibody production methods
|
|
KR20230107260A
(ko)
|
2020-11-12 |
2023-07-14 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
Sars-cov-2 스파이크 단백질의 수용체-결합 도메인에 접합되거나 융합된 항체, 및 백신 목적을 위한 이의 용도
|
|
US20240131138A1
(en)
|
2020-12-23 |
2024-04-25 |
Institut National De La Santé Et De La Recherche Médicale (Inserm) |
Chlamydia vaccine based on targeting momp vs4 antigen to antigen presenting cells
|
|
WO2022147481A1
(en)
|
2020-12-30 |
2022-07-07 |
Ansun Biopharma Inc. |
Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen
|
|
AU2022205370A1
(en)
*
|
2021-01-08 |
2023-08-24 |
Bristol-Myers Squibb Company |
Antibodies and antigen binding peptides for factor xia inhibitors and uses thereof
|
|
US20240173442A1
(en)
|
2021-01-13 |
2024-05-30 |
Hoffmann-La Roche Inc. |
Combination therapy
|
|
EP4284832A1
(en)
|
2021-01-29 |
2023-12-06 |
(INSERM) Institut National de la Santé et de la Recherche Médicale |
Chlamydia trachomatis antigenic polypeptides and uses thereof for vaccine purposes
|
|
WO2022165260A1
(en)
|
2021-01-29 |
2022-08-04 |
Iovance Biotherapeutics, Inc. |
Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
|
|
US12245355B2
(en)
|
2021-02-19 |
2025-03-04 |
Mevion Medical Systems, Inc. |
Gantry for a particle therapy system
|
|
EP4305066A1
(en)
|
2021-03-09 |
2024-01-17 |
Genmab A/S |
Multispecific binding agents against cd40 and cd137 in therapy
|
|
US20220325287A1
(en)
|
2021-03-31 |
2022-10-13 |
Flagship Pioneering Innovations V, Inc. |
Thanotransmission polypeptides and their use in treating cancer
|
|
AR126089A1
(es)
|
2021-06-07 |
2023-09-13 |
Amgen Inc |
Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas
|
|
EP4365200A4
(en)
*
|
2021-06-28 |
2025-04-09 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
ANTI-CD40 ANTIBODY, ANTIGEN-BINDING FRAGMENT AND MEDICAL USE THEREOF
|
|
KR20240026507A
(ko)
|
2021-06-29 |
2024-02-28 |
플래그쉽 파이어니어링 이노베이션스 브이, 인크. |
타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
|
|
CA3225254A1
(en)
|
2021-07-13 |
2023-01-19 |
BioNTech SE |
Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
|
|
WO2023044048A1
(en)
*
|
2021-09-17 |
2023-03-23 |
Novartis Ag |
Methods for prevention of graft rejection in xenotransplantation
|
|
CN118139886A
(zh)
*
|
2021-10-01 |
2024-06-04 |
Mab发现股份有限公司 |
作为免疫刺激剂的激动性cd40抗体
|
|
WO2023059607A1
(en)
|
2021-10-05 |
2023-04-13 |
Amgen Inc. |
Fc-gamma receptor ii binding and glycan content
|
|
US12234294B2
(en)
|
2021-11-05 |
2025-02-25 |
Kiniksa Pharmaceuticals, Gmbh |
Pharmaceutical composition of a humanized anti-CD40 antibody
|
|
EP4433504A1
(en)
|
2021-11-17 |
2024-09-25 |
Institut National de la Santé et de la Recherche Médicale |
Universal sarbecovirus vaccines
|
|
WO2023147488A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
|
IL315487A
(en)
*
|
2022-03-07 |
2024-11-01 |
Agenus Inc |
ANTI-ILT2 antibodies and their uses
|
|
WO2023193239A1
(en)
|
2022-04-08 |
2023-10-12 |
Peter Peizhi Luo |
Anti-cd28 antibodies and methods of use thereof
|
|
WO2023198851A1
(en)
|
2022-04-14 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for controlling the tumor cell killing by light
|
|
WO2023215725A1
(en)
|
2022-05-02 |
2023-11-09 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
|
CA3257929A1
(en)
|
2022-05-31 |
2025-04-22 |
Futuregen Biopharmaceutical (Beijing) Co., Ltd. |
Anti-CD40 antibodies, bispecific anti-PD-L1×CD40 antibodies, and their use
|
|
WO2024054992A1
(en)
|
2022-09-09 |
2024-03-14 |
Bristol-Myers Squibb Company |
Methods of separating chelator
|
|
CA3262796A1
(en)
*
|
2022-09-20 |
2024-03-28 |
Currus Biologics Pty Ltd |
Bispecific Polypeptides and Their Uses
|
|
EP4598576A1
(en)
*
|
2022-10-04 |
2025-08-13 |
Memorial Sloan-Kettering Cancer Center |
Anti-cd40 antibodies and uses thereof
|
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
|
EP4598953A1
(en)
|
2022-10-05 |
2025-08-13 |
Institut National de la Santé et de la Recherche Médicale |
Dc-targeting vaccine against nipah virus infection
|
|
WO2024118836A1
(en)
|
2022-11-30 |
2024-06-06 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes with shortened rep step
|
|
CN120302979A
(zh)
|
2022-12-01 |
2025-07-11 |
生物技术公司 |
针对CD40和CD137的多特异性抗体与抗PD1 Ab和化学治疗的组合治疗
|
|
CN115969997B
(zh)
*
|
2022-12-19 |
2024-02-13 |
华润生物医药有限公司 |
一种靶向cldn18.2的抗体药物偶联物及其应用
|
|
CN116375870B
(zh)
*
|
2022-12-30 |
2023-09-15 |
优睿赛思(武汉)生物科技有限公司 |
抗人cd40蛋白的人源化抗体、制备方法及其应用
|
|
US20240269251A1
(en)
|
2023-01-09 |
2024-08-15 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
WO2024213635A1
(en)
*
|
2023-04-12 |
2024-10-17 |
Evotec International Gmbh |
Interferon-associated antigen binding proteins for use for the treatment or prevention of hepatitis delta virus infection
|
|
AU2024256160A1
(en)
|
2023-04-20 |
2025-10-02 |
Amgen Inc. |
Methods of determining relative unpaired glycan content
|
|
AU2024325342A1
(en)
|
2023-08-14 |
2026-02-26 |
Amgen Inc. |
Methods for reducing yellow color
|
|
WO2025250159A2
(en)
*
|
2023-08-24 |
2025-12-04 |
The Trustees Of Columbia University In The City Of New York |
N-linked glycan removal mutant antibodies and their use against influenza viruses
|
|
WO2025101820A1
(en)
|
2023-11-08 |
2025-05-15 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
|
CN120424223A
(zh)
*
|
2024-02-04 |
2025-08-05 |
苏州泽璟生物制药股份有限公司 |
包含lrrc15抗原结合结构域的多特异性抗体
|
|
WO2025245964A1
(zh)
*
|
2024-05-28 |
2025-12-04 |
中生康元生物科技(北京)有限公司 |
一种树突状细胞制剂及其制备方法
|
|
WO2026090253A1
(en)
|
2024-10-23 |
2026-04-30 |
Amgen Inc. |
Methods of determining glycan pairing content
|